Global Epidermolysis Bullosa Therapeutics Market 2019-2023

Industry Insights

The global epidermolysis bullosa therapeutics market size will grow by USD 304.67 million during 2019-2023 at a CAGR of nearly 5%. The rising funds for research on epidermolysis bullosa and strong pipeline projects are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by product (antibiotics, analgesics, and other therapeutics) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Amryt Pharma, Fresenius, Johnson & Johnson, Novartis, and Pfizer.

Epidermolysis bullosa is a rare genetic disease that causes blistering and fragile skin. The current supportive treatment of epidermolysis bullosa includes wound care, pain control, controlling infections, and nutritional support.

Key Insights from Epidermolysis Bullosa Therapeutics Market – Global Forecast 2019-2023

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the epidermolysis bullosa therapeutics market report

Request a FREE sample now!

Increasing funds for research on epidermolysis bullosa is one of the critical reasons that will drive the growth of the epidermolysis bullosa therapeutics market. The available medications for the treatment of epidermolysis bullosa have side effects. This is encouraging private organizations and various governments to develop promising therapeutics with better safety and efficacy by releasing funds to advance the research. For instance, EB Research Partnership is partnering with individual donors, non-profit and profit organizations, research communities, and foundations in the US to raise funds. This has resulted in the development of novel therapeutic drugs such as diacerein ointment, which is used for the treatment of epidermolysis bullosa simplex.

The growing focus on strengthening the pipeline will enable pharmaceutical companies to provide effective treatment for epidermolysis bullosa without side effects. This will drive the epidermolysis bullosa therapeutics market to grow at a CAGR of almost 5% during the forecast period. For instance, a biopharmaceutical company, RegeneRx, announced that it had been preparing to start Phase III clinical trial in 2019 to test RGN-137. RGN-137 is a dermal gel, which is used to treat wounds caused by epidermolysis bullosa.

Industry Analysis

Product Insights

The product segment has been segregated into antibiotics, analgesics, and other therapeutics. The antibiotics segment accounted for the highest epidermolysis bullosa therapeutics market share in 2018. During the forecast period, the other therapeutics segment will grow at a faster pace than the overall market. The antibiotics and analgesics segments will grow at a slower pace than the overall market.

The antibiotics segment will account for the highest market share in the epidermolysis bullosa therapeutics market due to the recent approvals of broad-spectrum combinational antibiotics for the treatment of hospital infections that are easily developed in patients with epidermolysis bullosa.

Regional Insights

North America accounted for the highest market share in 2018. Though the market’s growth in this region will be slower than the growth of the market in Asia, Europe and ROW, the region will account for the largest epidermolysis bullosa therapeutics market share throughout the forecast period. The US is a key market for epidermolysis bullosa therapeutics in this region.

The increasing awareness about epidermolysis bullosa is one of the major reasons for the high growth of the epidermolysis bullosa therapeutics market in this region.

Top Epidermolysis Bullosa Therapeutics Companies

The epidermolysis bullosa therapeutics market is fragmented. To help clients improve their position, this epidermolysis bullosa therapeutics market analysis report provides information on the competitive landscape and the products offered by various companies. Moreover, this epidermolysis bullosa therapeutics market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.

The report offers a detailed analysis of several leading epidermolysis bullosa therapeutics manufacturers, including:

• Amryt Pharma
• Fresenius
• Johnson & Johnson
• Novartis
• Pfizer

Segments Covered in the Report

Epidermolysis bullosa therapeutics market by product

• Antibiotics
• Analgesics
• Other therapeutics

Epidermolysis bullosa therapeutics market by region

• Asia
• Europe
• North America
• ROW

Key Highlights of the Epidermolysis Bullosa Therapeutics Market Forecast Report for the Period 2019-2023 

• CAGR of the market during the forecast period 2019-2023 
• Detailed information on factors that will accelerate the growth of the epidermolysis bullosa therapeutics market size during the next five years 
• Precise estimation of the global epidermolysis bullosa therapeutics market size and its contribution to the parent market 
• Accurate predictions on upcoming trends and changes in consumer behavior 
• The growth of the epidermolysis bullosa therapeutics industry across Asia, Europe, North America, and ROW 
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors 
• Comprehensive details of factors that will challenge the growth of epidermolysis bullosa therapeutics companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch